STOX1 promotor region -922 T > C polymorphism is associated with Early-Onset preeclampsia
Seyda Akin1, Ergun Pinarbasi1, Aslihan Esra Bildirici1,2
1Faculty of Medicine, Department of Medical Biology, Sivas Cumhuriyet University, Sivas, Türkiye.
Insights
Genetic variants in the STOX1 gene promoter are linked to preeclampsia (PE), particularly early-onset PE. This finding highlights STOX1
Area of Science:
- Genetics
- Obstetrics
- Molecular Biology
Background:
- Preeclampsia (PE) affects 5-8% of pregnancies, posing risks to mother and fetus.
- The STOX1 gene has known variants associated with PE and HELLP syndrome.
- Previous research linked STOX1 polymorphisms to early-onset PE.
Purpose of the Study:
- To investigate the role of STOX1 gene promoter region variants in preeclampsia.
- To analyze the maternal genotype's effect on STOX1 expression in PE.
Main Methods:
- Sanger sequencing was used to analyze blood samples from 118 PE patients and 96 healthy pregnant women.
- Sequence analysis focused on the promoter region of the STOX1 gene.
Main Results:
- A specific polymorphism, -922 T>C (rs884181), was identified in the STOX1 promoter region.
- This polymorphism showed a statistically significant association with early-onset PE (p=0.02) and overall PE (p=0.014).
Conclusions:
- STOX1 promoter variations are significantly associated with preeclampsia, especially early-onset cases.
- These findings emphasize the importance of STOX1 in PE pathogenesis and disease risk.
- Further research into STOX1 variations could inform PE prevention and treatment strategies.
Abstract:
Preeclampsia (PE), affecting 5-8% of pregnancies, is a common pregnancy disease that has harmful effects on mother and foetus. It has been found that the STOX1 (Storkhead Box 1), which is a transcription factor, carries variants associated with PE. Previous studies showed that, there was a strong relationship between PE and STOX1 variants. Therefore, we hypothesised that variants in the promoter region of the gene may be related to the onset of PE. The aim of this study is to investigate the contribution of STOX1 gene promoter region variants to PE. The blood samples taken from 118 PE patients and 96 healthy pregnant women were analysed by Sanger sequencing method. Sequence analysis results showed that, there is a-922 T > C polymorphism (rs884181) in the promoter region of the STOX1 gene. This polymorphism was found to be statistically significant in individuals with early onset PE (p = 0.02) and in PE (p = 0.014) compared to the control group.IMPACT STATEMENTWhat is already known on this subject? As a result of whole-exon studies on the STOX1 gene, polymorphisms were found to disrupt the structure/expression/function of the gene and strengthen its relationship with PE and HELLP syndrome. A previous study by our team found an association between Y153H, the most common polymorphism of STOX1, and early onset PE.What do the results of this study add? In our study, it was aimed to investigate the effect of genetic modifications in STOX1 gene promoter region on PE through the maternal genotype. Because any change in the promoter region affects the expression level of the gene. Also, for the first time, sequence analysis of the promoter region of STOX1 is investigated in PE. The variations in STOX1 appear to be important in PE especially in Early Onset PE.What are the implications of these findings for clinical practice and/or further research? Although PE is a disease that occurs with pregnancy and shows its effects most during this period, women and children with a history of PE are more prone to various disorders, especially cardiovascular diseases in the following years. Therefore, understanding the pathogenesis of the disease is important for both prevention and treatment process. Variations on STOX1 appear to be important in terms of disease risk.
More Related Videos
Related Concept Videos
Pleiotropy
Cell Specific Gene Expression
Single Nucleotide Polymorphisms-SNPs
Exon Recombination
Exon shuffling follows “splice frame rules.” Each exon...
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...


